Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 3/20 | 0.53 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.53 |
| ▸ | HTR3A | P46098 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.52 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.52 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.52 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.52 |
| ▸ | HTR2B | P41595 | 1/20 | 0.52 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1118662 | 0.83 | KEAP1 (0.52) | GRIN1GRIN2BHTR3AHIF1ALMNA | |
| SCHEMBL8393618 | 0.79 | ALDH1A1 (0.61) | GRIN1GRIN2BHIF1ALMNATSHR | |
| SCHEMBL7630047 | 0.79 | NOS1 (0.57) | GRIN1GRIN2BHTR3AHIF1ALMNA | |
| SCHEMBL689470 | 0.78 | GRIN2B (0.50) | GRIN1GRIN2BHIF1ASMN1; SMN2SCN2A | |
| SCHEMBL5509994 | 0.78 | CHRNA7 (0.53) | MAPTCYP2A6 | |
| SCHEMBL8010207 | 0.78 | GRIN1 (0.52) | GRIN1GRIN2BHIF1ALMNATSHR | |
| SCHEMBL5504605 | 0.78 | CES1 (0.50) | GRIN1GRIN2BHIF1ALMNATSHR | |
| Urea SCHEMBL2006220 | 0.77 | FFAR1 (0.62) | HTR3ALMNAADRA1ASLC6A3SMN1; SMN2 | |
| Carbamic Acid SCHEMBL2222080 | 0.77 | FFAR1 (0.62) | HTR3ALMNAADRA1ASLC6A3SMN1; SMN2 | |
| Carbamic Acid SCHEMBL8092472 | 0.75 | FFAR1 (0.60) | LMNAADRA1ASLC6A3SMN1; SMN2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5401766-A | Hypotensive agents with vasodilation | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-03-28 | — | — | US | claimed |
| US-5158959-A | Treatment of hypertension | HOECHST AKTIENGESELLSCHAFT (DE) | 1992-10-27 | — | — | US | claimed |
| US-7223755-B2 | Hydroxymorpholinone derivative and medicinal use thereof | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2007-05-29 | — | — | US | disclosed |
| EP-1654244-A1 | 3-ARYL-4-HYDROXYFURANONE COMPOUNDS AND PHARMACEUTICAL AND VETERINARY COMPOSITIONS CONTAINING THEM | Wyeth (US) | 2006-05-10 | — | — | EP | disclosed |
| US-20060052627-A1 | Novel modulators of the PPAR-type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2006-03-09 | — | — | US | disclosed |
| US-20060035969-A1 | Novel modulators of the PPAR-type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2006-02-16 | — | — | US | disclosed |
| US-20050176704-A1 | Hydroxymorpholinone derivative and medicinal use thereof | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2005-08-11 | — | — | US | disclosed |
| WO-2005019196-A1 | 3-ARYL-4-HYDROXYFURANONE COMPOUNDS AND PHARMACEUTICAL AND VETERINARY COMPOSITIONS CONTAINING THEM | WYETH (US) | 2005-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176704-A1 | Hydroxymorpholinone derivative and medicinal use thereof | CAPN1, OPRM1, CAPN2 | GRIN1 70/4885GRIN2B 74/4885HTR3A 22/4885 |
| US-20060052627-A1 | Novel modulators of the PPAR-type receptors and cosmetic/pharmaceutical compositions comprised thereof | PPARG, PPARD, PPARA | GRIN1 1564/4885GRIN2B 1620/4885HTR3A 1087/4885 |
| US-20060035969-A1 | Novel modulators of the PPAR-type receptors and cosmetic/pharmaceutical compositions comprised thereof | PPARG, PPARD, PPARA | GRIN1 1564/4885GRIN2B 1620/4885HTR3A 1087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.